Nutritional Supplement Based on Myo-inositol-D-chiro-inositoln in Long-term Survivors of Lymphoma (Linf-inositol)

Nutritional Supplement Based on Myo-inositol-D-chiro-inositol: Effectiveness on the Reproductive System Functionality in Long-term Survivors of Lymphoma

The progressive improvement of lymphoma treatment has led to an important prolongation of patient survival and life expectancy. Therefore, the principal International scientific societies of oncology, recommend Long-term Survivors of Lymphoma to join fertility programs. Specifically, fertile age patients should be assisted by a multi-disciplinary team including specialists dedicated to fertility preservation in oncology, in order to support the completion of the reproductive project. In general population, the use of Inositol was spready considered an effectives choice to contrast ovarian dysfunction with consequently improvement of reproductive outcomes, so it may represent an adjuvant strategy for this purpose. Therefore, the investigators conducted a pilot study to evaluate the potentialities of this nutritional supplement with the aim to optimize the reproductive function in Long-term Survivors of Lymphoma. Despite the limited number of cases and short observational time, this pilot investigation could represent a potential cornerstone for further insights, discussions, and applications

Study Overview

• Status: Completed
• Conditions: Menstrual Irregularity; Fertility Disorders; Lymphoma, Hodgkin
• Intervention / Treatment: Drug: Myo-Inositol and D-Chiro-Inositol (MIC)

Detailed Description

Anticancer regimens are usually used to treat patients with lymphoproliferative neoplasms with a consequently transitory or permanent damage to their reproductive functionalities. Rates of gonadotoxicity of each chemotherapy could be modulated according to dose intensity, number of courses, and type of agent or combination. Classical Hodgkin lymphoma (cHL) and Diffuse Large B-cell lymphoma (DLBCL), including primary mediastinal Large B-cell Lymphoma (PMBL) have usually higher incidence in the 2nd or 3rd decade of life and presents cure rates of more than 75% 3,4 These histotypes need a poli-chemotherapy with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine), which involves the association of alkylating and non-alkylating agents.

The autologous hemato-poietic stem cell transplant (ASCT) is needed in about the 10% of cHL and the 40% of DLBCL and has higher impact on fertility compared to ABVD 6. Therefore, both the chemotherapy (damaging the primordial follicle pool and then the ovarian reserve, OR) and the radiotherapy (exclusively secondary to under diaphragmatic and pelvic irradiation) could represent a risk of gonadotoxicity . In this scenario, data concerning fertility in cHL have been mainly evaluated by the German Hodgkin Study Group (GHSG) and the European Organization for Research and Treatment of Cancer (EORTC) through amenorrhea and anti-Mullerian hormone (AMH) evaluation. Indeed, amenorrhea has been used in numerous research to assess the gonadotoxicity of oncological treatment and reflect ovarian function . Furthermore, AMH could represent a gonadotoxicity marker, since it decreases during chemotherapy and could improve after the end of treatment, depending upon specific treatment schemes . Literature showed that after early-stage disease treatment (2 -4 cycle), more than 90% of patients reported a low gonadotoxic effect with a regular menstrual cycle after therapy (median recovery of 1 year). For advanced stage diseases (treated with 6 courses of ABVD) the gonadotoxic effect vary on base of patient's aged. Indeed, the complete AMH restoring during the 3-years follow-up period, was detected in all women under 35 years, and only 37% of older ones . Moreover, in a Cochrane meta-analysis, gonadotropin-releasing hormone agonist (GnRHa)seems to be effective in shielding the ovaries during chemotherapy, in terms of treatment-related premature ovarian failure, ovulation and menstruation recovery.

Beyond the ovarian suppression with GnRHa, there are several well-established procedures (oocyte cryopreservation, ovarian cortex cryopreservation for woman and sperm cryopreservation for men) that could prevent impact of these therapies in young patients. Therefore, considering the increased life expectation nowadays of Long-term Survivors of Lymphoma (patients in complete remission of the disease for more than 5 years) a fertility program with multi-disciplinary counselling is indicated. Particularly, in order to assess the damages upcoming after anticancer therapies on reproductive organs, international scientific societies such as the American Society for Reproductive Medicine (ASRM) (Ethics Committee of American Society for Reproductive Medicine, 2013), the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO) as well as the International Society for Fertility Preservation (ISFP), strongly recommend a personalized and multidisciplinary counseling for each patient. In particular, the surveillance programs for the management of long-term lymphoma survivors should involve a team with onco-hematologists, radiotherapists, cardiologists, an endocrinologist, a psychologist, gynecologist, urologist and a nutritional biologist. The goal is to provide individualized therapeutic possibilities to restore endocrine function. Following these recommendations, an ambulatorial service dedicated to fertile patients with oncological disease was instituted in our Clinic of Gynecology Oncology, aiming to perform a careful assessment of the fertility state and support the reproductive project of those patients.

In these women,the investigators primarily estimated AMH, Follicle stimulating hormone (FSH), Luteinizing hormones (LH), 17β-estradiol ,in association to antral follicles count (AFC) assessed by ultrasonography during the cycle follicular phase. During this clinical evaluation, several patients often reported menstrual irregularities due to anovulatory cycles (50%), dysmenorrhea (20%) and abnormal uterine bleeding (30%).

Considering these elements, one of the potential therapeutic options could be considered the oral supplementation with Myo-Inositol and D-Chiro-Inositol (MIC). Indeed, MIC over the years has tiptoed to come alongside the classic pharmacological therapies, with robust compliance, safety, and effectiveness. MIC showed great potentiality to contrast ovarian dysfunction and optimize the reproductive function.

Therefore, the investigators conducted a prospective observational controlled study, with the aim to assess the effects of oral supplementation with MIC on ovarian function parameters in Long-term Survivors of Lymphoma.

• Study Type: Observational
• Enrollment (Actual): 90

Contacts and Locations

Study Locations

• Italy
  • Bari, Italy, 70124
    • IRCCS - Istituto Oncologico"Giovanni PaoloII"

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 25 years to 44 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

• Sampling Method: Probability Sample

Study Population

From January 2020 to January 2021, 90 Long-term Survivors of Lymphoma female patients, average age 34 years (range 25-44) were considered eligible for the study. Each patient was informed about the procedures and signed informed consent before the surgery to allow data collection for research purposes.

Description

Inclusion Criteria:

• Patients with Classical Hodgkin lymphoma (cHL) and Diffuse Large B-cell lymphoma (DLBCL) long survival

Exclusion Criteria:

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Other

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

cHL (85%) and DLBCL (15%); Patients enrolled in this study are cHL (85%) and DLBCL (15%) long-term survivors, treated mainly with ABVD+ radiotherapy (not under diaphragmatic and pelvic irradiation), without relapse (during quinquennial follow-up) who are followed at the clinic dedicated to fertility in oncology of our Department, which is a regional referral center for this purpose. Therefore, the investigators conducted a prospective observational controlled study on two groups: the first one (A group) underwent oral supplementation with MIC for 12 months; the second group (B group) underwent follow-up without any nutritional supplement for 12 months

Drug: Myo-Inositol and D-Chiro-Inositol (MIC); Both groups were followed up for 12 months, in T0 (during first evaluation), and T12 (after twelve months) with blood test for AMH (ng/ml).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Lymphoma long-term survivors treated with myo-inositol-D-chiro-inositol: evaluation of the results on the reproduction apparatus	The investigatirs conducted a prospective observational controlled study on two groups: the first one (A group) underwent oral supplementation with myo-inositol-D-chiro-inositol for 12 months; the second group (B group) underwent follow-up without any nutritional supplement for 12 months.Moreover, the investigators reported for each patient the menstrual frequency ( oligomenorrhea <25 days , normal flow 25-36 days , polymenorrhea >36 days), the duration of the cycle (short < 3 days, normal: 3-7 days , long >7 days), the amount of the menstrual cycle (poor <30 ml, normal 30-80 ml, >80 ml abundant) and dysmenorrhea and dyspareunia (visual analogue scale VAS pain scale = 1 -10).In addition, results of blood tests and clinical data about menstrual regularity and dysmenorrhea, were reported on the same database.In addition, results of blood tests and clinical data about menstrual regularity and dysmenorrhea, were reported on the same database.	12 months

Collaborators and Investigators

• Sponsor: University of Bari Aldo Moro

Study record dates

Study Major Dates

• Study Start (Actual): February 7, 2020
• Primary Completion (Actual): February 7, 2021
• Study Completion (Actual): December 7, 2021

Study Registration Dates

• First Submitted: May 29, 2022
• First Submitted That Met QC Criteria: June 2, 2022
• First Posted (Actual): June 8, 2022

Study Record Updates

• Last Update Posted (Actual): June 8, 2022
• Last Update Submitted That Met QC Criteria: June 2, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma; Menstruation Disturbances; Hodgkin Disease; Physiological Effects of Drugs; Micronutrients; Vitamins; Vitamin B Complex; Inositol
• Other Study ID Numbers: UNIBA

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: From January 2020 to January 2021, 90 Long-term Survivors of Lymphoma female patients, average age 34 years (range 25-44) were considered eligible for the study.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No